Why is the U.S. government investigating GlaxoSmithKline now?
GlaxoSmithKline recently said U.S. enforcement agencies asked for information about third-party advisers the company hired in China during a corruption investigation in the country. The Man From FCPA asks, why now?
Related articles
-
PremiumEmerging Compliance Risks 2025: Laurie Waddy on Leadership, Anticorruption, and AI
Former Head of Compliance/Chief Compliance Officer Laurie Waddy believes compliance professionals are well-positioned to support artificial intelligence (AI) adoption in their organizations. Drawing on 25 years’ experience in legal and compliance roles across multiple industries, Waddy shares insights into top compliance trends confronting the profession, including the emerging compliance risks ...
-
News BriefDOJ declines to prosecute Liberty Mutual in $4.7M FCPA bribery case
Liberty Mutual agreed to give up $4.7 million in profit – the amount it earned from a bribery scheme uncovered by the government – as part of a settlement related to the Foreign Corrupt Practices Act, according to a letter from the U.S. Department of Justice.
-
News BriefDOJ targets $14.6B in health care fraud with focus on transnational crime
Emerging enforcement priorities of the U.S. Department of Justice’s health care fraud division align with the Trump administration’s emphasis on prosecuting transnational criminal organizations and ending opioid trafficking.